Evidence map›Paper›PMID 25949897›Full record

ArticleOncoimmunology2015

Characterization of the

I Chevolet, R Speeckaert, M Schreuer, B Neyns, O Krysko, C Bachert, B Hennart, D Allorge, N van Geel, M Van Gele and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 109 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 3 countries.

I ChevoletDepartment of Dermatology; Ghent University Hospital Ghent, Belgium.
R SpeeckaertDepartment of Dermatology; Ghent University Hospital Ghent, Belgium.
M SchreuerDepartment of Medical Oncology ; UZ-Brussel ; Brussels, Belgium ; Department of Medical Oncology; Ghent University Hospital ; Ghent, Belgium.
B NeynsDepartment of Medical Oncology ; UZ-Brussel ; Brussels, Belgium.
O KryskoUpper Airways Research Laboratory; Ghent University Hospital ; Ghent, Belgium.
C BachertUpper Airways Research Laboratory; Ghent University Hospital ; Ghent, Belgium.
B HennartLaboratoire de Toxicologie; CHU Lille ; Lille, France.
D AllorgeLaboratoire de Toxicologie; CHU Lille ; Lille, France.
N van GeelDepartment of Dermatology; Ghent University Hospital Ghent, Belgium.
M Van GeleDepartment of Dermatology; Ghent University Hospital Ghent, Belgium.
L BrochezDepartment of Dermatology; Ghent University Hospital Ghent, Belgium.
Ghent University Hospital · BECentre Hospitalier Universitaire de Lille · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In melanoma, both the induction of immunosuppression by tumor cells and the inflammatory antitumor response can induce an upregulation of counter-regulatory mechanisms such as indoleamine 2,3-dioxygenase (IDO), programmed death-ligand 1 (PD-L1) and CTLA-4

Indexed as

AJCCAmerican Joint Committee on Cancer systemCC, correlation coefficientCTLA-4Cytotoxic T Lymphocyte-Associated Antigen 4cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)DC, dendritic cellsHR, hazard ratioIDO, indoleamine 2, 3-dioxygenaseIFNγ, interferon-gammaindoleamine 2-3-dioxygenase (IDO)IQR, interquartile rangeKyn, kynureninemDC, myeloid DCMDSC, myeloid-derived suppressor cellsmelanomaMFI, mean fluorescence intensitymMDSC, monocytic MDSCnegative feedback mechanismOS, overall survivalPBMC, peripheral blood mononuclear cellsPD-1, programmed cell death protein 1pDC, plasmacytoid DCPD-L1, Programmed-Death Ligand 1pmnMDSC, polymorphonuclear MDSCprognosisprogrammed-death ligand 1 (PD-L1)regulatory T-cellsTreg, regulatory T-cellTryp, tryptophanUPLC, ultra-performance liquid chromatography

Identifiers

PMID25949897
PMCPMC4404886
OpenAlexW2163946328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.